Correlation Between Resistin Level and Metabolic Syndrome Component: A Review

Abstract

Metabolic syndrome (MetS) has a collection of some abnormal and pathological conditions that cause many critical diseases. Resistin is one of the possible candidates for these pathologies but there are not enough data to prove if resistin has positive, neutral, or negative effects on one or some components of MetS. This review summarizes data about comparing the effects and contribution of resistin in initiation and progression of MetS components and also its different actions between human and other mammalians. This summarized data about the relationship of resistin and MetS components have been obtained from clinical researches and in some cases even animal studies. To find the relevant studies, the search in PubMed, Science Direct, and Scopus were performed. Human and animal studies on relationships between resistin and MetS (initiation and progression of components) were included in our search. In experiments reported among different human genetic groups as well as the patients with various disease such as diabetes, no significant correlation is shown between FBG and resistin level. Furthermore, this review shows that the results of correlation between resistin and TG, HDL, and central or abdominal obesity were inconsistent. These inconsistencies can arise from different sample size or genetic groups, gender, and also from experimental studies. Therefore, to obtain precise results systematic review and meta-analyses are required.

Key words

correlation - resistin - metabolic syndrome

• References

• 1 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428
• 2 Harrabi I, Bouaouina M, Maatoug J, Gaha R, Ghannem H. Prevalence of the metabolic syndrome among urban schoolchildren in Sousse, Tunisia. Int J Cardiol 2009; 135: 130-131
• 3 Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci (Landmark edition) 2010; 16: 1663-1674
• 4 Nikolopoulou A, Kadoglou NP. Obesity and metabolic syndrome as related to cardiovascular disease. Exp Rev Cardiovasc Ther 2012; 10: 933-939
• 5 Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. J Parenter Enteral Nutr 2008; 32: 638-644
• 6 Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
• 7 McTernan CL, McTernan PG, Harte AL, Levick P, Barnett A, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-47
• 8 Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, Buring JE, Gaziano JM, Liu S. Circulating levels of resistin and risk of type 2 diabetes in men and women: Results from two prospective cohorts. Diabetes Care 2009; 32: 329-334
• 9 Momiyama Y, Ohmori R, Uto-Kondo H, Tanaka N, Kato R, Taniguchi H, Arakawa K, Nakamura H, Ohsuzu F. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2011; 18: 108-114
• 10 Ukkola O. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander?. Eur J Endocrinol 2002; 147: 571-574
• 11 Asgary S, SamsamShariat SZ, Ghorbani A, Keshvari M, Sahebkar A, Sarrafzadegan N. Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population. Diabetes Metab Syndr: Clin Res Rev 2015; 9: 266-270
• 12 Lazar M. Resistin-and obesity-associated metabolic diseases. Horm Metab Res 2007; 39: 710-716
• 13 Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A 2001; 98: 502-506
• 14 Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, Barzilai N, Scherer PE. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-a in adipose tissue. Mol Endocrinol 2002; 16: 1920-1930
• 15 Nogueiras R, Gallego R, Gualillo O, Caminos JE, García-Caballero T, Casanueva FF, Diéguez C. Resistin is expressed in different rat tissues and is regulated in a tissue-and gender-specific manner. FEBS Lett 2003; 548: 21-27
• 16 Nogueiras R, Barreiro ML, Caminos JE, Gaytán F, Suominen JS, Navarro VM, Casanueva FF, Aguilar E, Toppari J, Diéguez C. Novel expression of resistin in rat testis: Functional role and regulation by nutritional status and hormonal factors. J Cell Sci 2004; 117: 3247-3257
• 17 Morash BA, Willkinson D, Ur E, Wilkinson M. Resistin expression and regulation in mouse pituitary. FEBS Lett 2002; 526: 26-30
• 18 Del Arco A, Peralta S, Carrascosa J, Ros M, Andres A, Arribas C. Alternative splicing generates a novel non-secretable resistin isoform in Wistar rats. FEBS Lett 2003; 555: 243-249
• 19 Rak-Mardyła A, Duda M, Gregoraszczuk E. A role for resistin in the ovary during the estrous cycle. Horm Metab Res 2014; 46: 493-498
• 20 Fain JN, Cheema PS, Bahouth SW, Hiler ML. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003; 300: 674-678
• 21 Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPARg activators. Biochem Biophys Res Commun 2003; 300: 472-476
• 22 Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E, Thiery J, Kiess W, Kratzsch J. Serum resistin levels of obese and lean children and adolescents: Biochemical analysis and clinical relevance. J Clin Endocrinol Metab 2005; 90: 4503-4509
• 23 Schwartz DR, Lazar MA. Human resistin: Found in translation from mouse to man. Trends Endocrinol Metab 2011; 22: 259-265
• 24 Park HK, Kwak MK, Kim HJ, Ahima RS. Linking resistin, inflammation, and cardiometabolic diseases. Korean J Intern Med 2017; 32: 239
• 25 Satoh T, Akira S. Toll-like receptor signaling and its inducible proteins. Microbiol Spect 2016; 4
• 26 Hussein WM, Liu T-Y, Skwarczynski M, Toth I. Toll-like receptor agonists: a patent review (2011–2013). Exp Opin Therap Pat 2014; 24: 453-470
• 27 Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol 2014; 5: 461
• 28 Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010; 14: 1419-1431
• 29 Benomar Y, Gertler A, De Lacy P, Crépin D, Hamouda HO, Riffault L, Taouis M. Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 2013; 62: 102-114
• 30 Leifer CA, Medvedev AE. Molecular mechanisms of regulation of Toll-like receptor signaling. J Leuk Biol 2016; 100: 927-941
• 31 Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: A cell biological perspective. Ann Review Immunol 2015; 33: 257-290
• 32 Jia S-J, Niu P-P, Cong J-Z, Zhang B-K, Zhao M. TLR4 signaling: A potential therapeutic target in ischemic coronary artery disease. Int Immunopharm 2014; 23: 54-59
• 33 Reverchon M, Maillard V, Froment P, Ramé C, Dupont J. Adiponectine et résistine-Un rôle dans les fonctions de reproduction?. Méd/Sci 2013; 29: 417-424
• 34 Lee S, Lee H-C, Kwon Y-W, Lee SE, Cho Y, Kim J, Lee S, Kim J-Y, Lee J, Yang H-M. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 2014; 19: 484-497
• 35 Zhang H, Ghai P, Wu H, Wang C, Field J, Zhou G-L. Mammalian adenylyl cyclase-associated protein 1 (CAP1) regulates cofilin function, the actin cytoskeleton, and cell adhesion. J Biol Chem 2013; 288: 20966-20977
• 36 Jiang Y, Lu L, Hu Y, Li Q, An C, Yu X, Shu L, Chen A, Niu C, Zhou L. Resistin induces hypertension and insulin resistance in mice via a TLR4-dependent pathway. Sci Rep 2016; 6: 22193
• 37 Kosari S, Rathner JA, Chen F, Kosari S, Badoer E. Centrally administered resistin enhances sympathetic nerve activity to the hindlimb but attenuates the activity to brown adipose tissue. Endocrinology 2011; 152: 2626-2633
• 38 de Luis D, Sagrado MG, Conde R, Aller R, Izaola O, Primo D. Lack of association of serum resistin levels with metabolic syndrome criteria in obese female patients. Clin Biochem 2011; 44: 1280-1283
• 39 Papadopoulos DP, Perrea D, Thomopoulos C, Sanidas E, Daskalaki M, Papazachou U, Votteas V, Makris T. Masked hypertension and atherogenesis: The impact on adiponectin and resistin plasma levels. J Clin Hyperten 2009; 11: 61-65
• 40 Thomopoulos C, Daskalaki M, Papazachou O, Rodolakis N, Bratsas A, Papadopoulos D, Papavasileiou M, Perrea D, Makris T. Association of resistin and adiponectin with different clinical blood pressure phenotypes. J Hum Hyperten 2011; 25: 38
• 41 Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, Ochi M, Nishida W, Okura T, Higaki J, Makino H. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008; 51: 534-539
• 42 Papadopoulos D, Makris TK, Perrea D, Papazachou O, Daskalaki M, Sanidas E, Votteas V. Adiponectin–insulin and resistin plasma levels in young healthy offspring of patients with essential hypertension. Blood Pressure 2008; 17: 50-54
• 43 Zhang L, Curhan GC, Forman JP. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol 2010; 21: 1185-1191
• 44 Zhang Y, Li Y, Yu L, Zhou L. Association between serum resistin concentration and hypertension: A systematic review and meta-analysis. Oncotarget 2017; 8: 41529
• 45 Teng X, Li D, Champion HC, Johns RA. FIZZ1/RELMa, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circul Res 2003; 92: 1065-1067
• 46 Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal–regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-3340
• 47 Herichova I, Szantoova K. Renin-angiotensin system: Upgrade of recent knowledge and perspectives. Endocr Regul 2013; 47: 39-52
• 48 Liu Y, Wang Q, Pan Y-B, Gao Z-J, Liu Y-F, Chen S-H. Effects of over-expressing resistin on glucose and lipid metabolism in mice. J Zhejiang Uni-Sci B 2008; 9: 44-50
• 49 Sato N, Kobayashi K, Inoguchi T, Sonoda N, Imamura M, Sekiguchi N, Nakashima N, Nawata H. Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology 2005; 146: 273-279
• 50 Costandi J, Melone M, Zhao A, Rashid S. Human Resistin Stimulates Hepatic Overproduction of Atherogenic ApoB-Containing Lipoprotein Particles by Enhancing ApoB Stability and Impairing Intracellular Insulin SignalingNovelty and Significance. Circul Res 2011; 108: 727-742
• 51 Hsu B-G, Lee C-J, Yang C-F, Chen Y-C, Wang J-H. High serum resistin levels are associated with peripheral artery disease in the hypertensive patients. BMC Cardiovasc Disord 2017; 17: 80
• 52 Niu X-H, Li L, Li J-Y, Song Q, Jin M-M, Liu J-X. Serum resistin positively correlates with serum lipids, but not with insulin resistance, in first-degree relatives of type-2 diabetes patients: An observational study in China. Medicine (Baltimore) 2017; 96: e6622
• 53 Norata G, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano A. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156: 279-284
• 54 Singh AK, Tiwari S, Gupta A, Shukla KK, Chhabra KG, Pandey A, Pant AB. Association of resistin with insulin resistance and factors of metabolic syndrome in north Indians. Indian J. Clin Biochem 2015; 30: 255-262
• 55 Osawa H, Ochi M, Tabara Y, Kato K, Yamauchi J, Takata Y, Nishida W, Onuma H, Shimizu I, Fujii Y. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol 2008; 69: 74-80
• 56 De Luis D, Gonzalez Sagrado M, Conde R, Aller R, Izaola O. Resistin levels and inflammatory markers in patients with morbid obesity. Nutr Hosp 2010; 25: 630-634
• 57 de León AC, González DA, Hernández AG, Coello SD, Marrugat J, Sánchez JJA, Díaz BB, Rodríguez IM, Pérez MdCR. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J Atheroscler Thromb 2014; 21: 454-462
• 58 Jiang L-L, Li L, Hong X-F, Li Y-M, Zhang B-L. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol 2009; 21: 662-666
• 59 Owecki M, Nikisch E, Miczke A, Pupek-Musialik D, Sowiński J. Serum resistin is related to plasma HDL cholesterol and inversely correlated with LDL cholesterol in diabetic and obese humans. Neuroendocrinol Lett 2010; 31: 673-678
• 60 Singh AK, Tiwari S, Gupta A, Natu SM, Mittal B, Pant AB. Association of resistin with metabolic syndrome in Indian subjects. Metab Syndr Relat Disord 2012; 10: 286-291
• 61 Gupta V, Singh A, Gupta V, Kumar S, Srivastava N, Jafar T, Pant A. Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. Toxicol Int 2011; 18: 168
• 62 Bednarska-Makaruk M, Graban A, Wiśniewska A, Łojkowska W, Bochyńska A, Gugała-Iwaniuk M, Sławińska K, Ługowska A, Ryglewicz D, Wehr H. Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia. Biogerontology 2017; 1-20
• 63 Marcelino-Rodríguez I, Gonzalez DA, Alemán-Sánchez JJ, Díaz BB, Pérez MdCR, Gannar F, Coello SD, Fernández FJC, de León AC. Inverse association of resistin with physical activity in the general population. PloS One 2017; 12: e0182493
• 64 Nakata M, Okada T, Ozawa K, Yada T. Resistin induces insulin resistance in pancreatic islets to impair glucose-induced insulin release. Biochem Biophys Res Commun 2007; 353: 1046-1051
• 65 Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 2006; 49: 183-190
• 66 Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004; 53: 1937-1941
• 67 He Z-L, Chen Y, Ma J, Yu W-h, Li Y-Y, Yang F-M, Wang J-B, Chen L-X, Zhao Y, Lu S-Y. Relevance and clinical significance of serum resistin level in obese T2DM rhesus monkey models. Exp Clin Endocrinol Diabetes 2015; 123: 508-513
• 68 Canga A, Cetin M, Kocaman S, Durakoğlugil M, Kırbaş A, Erdoğan T, Temiz A, Yılmaz A, Çiçek Y. Increased serum resistin levels in patients with coronary slow-flow phenomenon. Herz 2013; 38: 773-778
• 69 Li M, He X, Qu S, Zhan H, Yang Y, Xu X, Si Y. Plasma resistin level in obstructive sleep apnea hypopnea syndrome. Zhonghua yi xue za zhi 2008; 88: 2399-2402
• 70 Chanchay S, Tungtrongchitr R, Harnroongroj T, Phonrat B, Rungseesakorn O, Paksanont S, Pooudong S, Saowakontha S, Varongchayakul C. Plasma resistin, insulin concentration in non-diabetic and diabetic, overweight/obese Thai. Int J Vitamin Nutr Res 2006; 76: 125-131
• 71 Liu G, Fu X, Jiang L, Ma X, Yang J. Serum resistin concentration and insulin resistance in obese children. Chin J Pediatr 2006; 44: 114-117
• 72 Lu H-L, Wang H-W, Wen Y, Zhang M-X, Lin H-H. Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes. World J Gastroenterol 2006; 12: 1747
• 73 Al-Harithy RN, Al-Ghemdi S. Serum resistin, adiposity and insulin resistance in Saudi. Ann Saudi Med 2005; 25: 283-287
• 74 Piestrzeniewicz K, Łuczak K, Komorowski J, Maciejewski M, Wika JJ, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 2008; 57: 488-493
• 75 Chen X-Y, Zhang J-H, Liu F, Liu H-M, Song Y-Y, Liu Y-L. Association of serum resistin levels with metabolic syndrome and early atherosclerosis in obese Chinese children. J Pediatr Endocrinol Metab 2013; 26: 855-860
• 76 Korah TE, Ibrahim HH, Badr EA, ElShafie MK. Serum resistin in acute myocardial infarction patients with and without diabetes mellitus. Postgrad Med J 2011; 2010: 113571
• 77 Janowska J, Zahorska-Markiewicz B, Olszanecka-Glinianowicz M. Relationship between serum resistin concentration and proinflammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism 2006; 55: 1495-1499
• 78 Filippidis G, Liakopoulos V, Mertens PR, Kiropoulos T, Stakias N, Verikouki C, Patsidis E, Koukoulis G, Stefanidis I. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purificat 2005; 23: 421-428
• 79 Barb D, Wadhwa SG, Kratzsch J, Gavrila A, Chan JL, Williams CJ, Karchmer AW, Mantzoros CS. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 5324-5328
• 80 de Courten BV, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004; 53: 1279-1284
• 81 Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 361-366
• 82 Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42: 62-66
• 83 Chen C-C, Li T-C, Li C-I, Liu C-S, Wang H-J, Lin C-C. Serum resistin level among healthy subjects: Relationship to anthropometric and metabolic parameters. Metabolism 2005; 54: 471-475
• 84 Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-1086
• 85 Bajnok L, Seres I, Varga Z, Jeges S, Peti A, Karanyi Z, Juhasz A, Csongradi E, Mezosi E, Nagy E. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes 2008; 116: 592-599
• 86 Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006; 91: 2755-2760
• 87 Won JC, Park C-Y, Lee WY, Lee ES, Oh SW, Park SW. Association of plasma levels of resistin with subcutaneous fat mass and markers of inflammation but not with metabolic determinants or insulin resistance. J Korean Med Sci 2009; 24: 695-700
• 88 Li M, Fisette A, Zhao X, Deng J, Mi J, Cianflone K. Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. Int J Obes 2009; 33: 424-439
• 89 Jain SH, Massaro JM, Hoffmann U, Rosito GA, Vasan RS, Raji A, O’donnell CJ, Meigs JB, Fox CS. Cross-sectional associations bet ween abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham heart study. Diabetes Care 2009; 32: 903-908
• 90 Asano H, Izawa H, Nagata K, Nakatochi M, Kobayashi M, Hirashiki A, Shintani S, Nishizawa T, Tanimura D, Naruse K. Plasma resistin concentration determined by common variants in the resistin gene and associated with metabolic traits in an aged Japanese population. Diabetologia 2010; 53: 234
• 91 Yongming Z, Muxun Z, Wei G, Meixia Y, Keying X, Shiang H, Yanhong C, Huanli Z, Lijun X, Tiecheng G. Expression of resistin protein in normal human subcutaneous adipose tissue and pregnant women subcutaneous adipose tissue and placenta. J Huazhong Uni Sci Technol [Medical Sciences] 2006; 26: 288-291
• 92 Coello SD, de León AC, González DA, Hernández AG, Pérez MR, Ramos NF, Díaz BB, Fuentes RC, Jaime AA. Inverse association between serum resistin and insulin resistance in humans. Diabetes Res Clin Pract 2008; 82: 256-261
• 93 Bahr MJ, Ockenga J, Böker KH, Manns MP, Tietge UJ. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E199-E206
• 94 Farvid M, Ng T, Chan D, Barrett P, Watts G. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 2005; 7: 406-413
• 95 Straburzynska-Lupa A, Nowak A, Pilaczynska-Szczesniak L, Straburzynska-Migaj E, Romanowski W, Karolkiewicz J, Sliwicka E. Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 19
• 96 Skoczylas A, Piecha G, Więcek A. Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. Polsk Arch Med Wewnetr 2016; 126: 243-253
• 97 Papadopoulos DP, Makris TK, Krespi PG, Poulakou M, Stavroulakis G, Hatzizacharias AN, Perrea D, Votteas VV. Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J Clin Hyperten 2005; 7: 729-733
• 98 Zhang J, Qin Y, Zheng X, Qiu J, Gong L, Mao H, Jia W, Guo J. The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure. Zhonghua yi xue za zhi 2002; 82: 1609-1612
• 99 Niaz S, Shirwany TAK. Serum resistin levels in patients of hypertension and coronary artery disease. Pakistan J Med Health Sci 2016; 10: 445-447
• 100 Rodríguez IM, Rodríguez C, Gannar F, Brito B, Almeida D, Alemán J, Domínguez S, De León AC. PP. 16.06: Rsesistin, blood pressure and cardiovascular events. J Hyperten 2015; 33: e271
• 101 Musialik K, Bogdański P, Szulińska M. Ocena stężenia rezystyny u otyłych pacjentów z nadciśnieniem tętniczym. Arter Hyperten 2010; 14: 48-54
• 102 Gürsoy G, Ulu S, Acar Y, Demirbaş B, Alkan S, Erol B, Özaşık I. Relation of resistın wıth obesity and some cardiovascular risk factors in hypertensive women. J Res Med Sci 2012; 17: 443
• 103 Takhshid MA, Zare Z. Resistin–420 C/G polymorphism and serum resistin level in Iranian patients with gestational diabetes mellitus. J Diabetes Metab Disord 2015; 14: 37
• 104 Kumar S, Gupta V, Srivastava N, Gupta V, Mishra S, Mishra S, Shankar MN, Roy U, Chandra A, Negi M. Resistin 420C/G gene polymorphism on circulating resistin, metabolic risk factors and insulin resistance in adult women. Immunol Lett 2014; 162: 287-291
• 105 Robati RM, Partovi-Kia M, Haghighatkhah HR, Younespour S, Abdollahimajd F. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: Is psoriasis associated with atherosclerosis?. J Am Acad Dermatol 2014; 71: 642-648
• 106 Huang F, del-Río-Navarro BE, Pérez-Ontiveros JA, Ruiz-Bedolla E, Saucedo-Ramírez OJ, Villafaña S, Bravo G, Mailloux-Salinas P, Hong E. Effect of six-month lifestyle intervention on adiponectin, resistin and soluble tumor necrosis factor-a receptors in obese adolescents. Endocr J 2014; 61: 921-931
• 107 Shen C, Zhao C-Y, Wang W, Wang Y-D, Sun H, Cao W, Yu W-Y, Zhang L, Ji R, Li M. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol 2014; 14: 39
• 108 Priya T, Chowdhury MG, Vasanth K, Vijayakumar TM, Ilango K, Agrawal A, Dubey GP. Withdrawn: Assessment of serum leptin and resistin levels in association with the metabolic risk factors of pre-and post-menopausal rural women in South India. Diabetes Metab Syndr: Clin Res Rev 2013; 7: 233-237
• 109 Boyraz M, Cekmez F, Karaoğlu A, Cinaz P, Durak M, Bideci A. Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children. Biomark Med 2013; 7: 423-428
• 110 Nehus E, Furth S, Warady B, Mitsnefes M. Correlates of resistin in children with chronic kidney disease: The chronic kidney disease in children cohort. J Pediatr 2012; 161: 276-280
• 111 Klemettilä J-P, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, Leinonen E. Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine. Nord J Psychiatr 2017; 71: 89-95
• 112 Joksić J, Sopic M, Spasojevic-Kalimanovska V, Kalimanovska-Ostric D, Andjelkovic K, Jelic-Ivanovic Z. Circulating resistin protein and mRNA concentrations and clinical severity of coronary artery disease. Biochem Med 2015; 25: 242-251
• 113 Qi Q, Wang J, Li H, Yu Z, Ye X, Hu FB, Franco OH, Pan A, Liu Y, Lin X. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol 2008; 159: 585-593
• 114 Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, Nishida W, Yamada K, Nakura J, Kohara K. Plasma resistin, associated with single nucleotide polymorphism− 420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 2007; 30: 1501-1506
• 115 Conneely KN, Silander K, Scott LJ, Mohlke KL, Lazaridis KN, Valle TT, Tuomilehto J, Bergman RN, Watanabe RM, Buchanan TA. Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects. Diabetologia 2004; 47: 1782-1788
• 116 Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457
• 117 De Luis D, Terroba M, Cuellar L, Conde R, Primo D, Aller R, Sagrado M, Izaola O. Resistin levels in morbid obese patients following the biliopancreatic diversion surgery. Horm Metab Res 2011; 43: 205-208
• 118 Zhang L-Y, Jin Y-J, Jin Q-S, Lin L-Y, Zhang D-D, Kong L-L. Association between resistin+ 299 A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus. Gene 2013; 529: 340-344
• 119 Arraiz N, Escalona C, Prieto C, Bermudez V, Mújica E, Sanchez M, Mújica A. 3′UTR+ 62 G> A polymorphism of the RETN gene coding resistin and its association with metabolic syndrome components. Med Clin 2013; 141: 325-331